Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Huntington Bancshares Incorporated — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Huntington Bancshares Incorporated trades at $17.45 (market cap $36.50B). The key difference: Huntington Bancshares Incorporated is far larger — about 8.1× ACADIA Pharmaceuticals Inc.'s market cap, and Huntington Bancshares Incorporated pays a 3.44% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HBAN | |
|---|---|---|
Market Cap | $4.49B | $36.50B |
Sector | Health | Financials |
52-Week High | $28.06 | $19.27 |
52-Week Low | $20.06 | $15.02 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Huntington Bancshares (HBAN) trades at $18.01, up 0.84% with bullish technical indicators and strong analyst support. The stock shows solid fundamentals with Q1 2026 EPS beating expectations at $0.26 vs. $0.23, revenue growth to $8.13B in 2025, and a reasonable P/E of 13.77. Recent news highlights successful Texas expansion and banking tech awards, while cash flow trends show consistent operational strength.
HBAN presents a compelling buy case with 51% analyst buy ratings and a $19.90 price target offering 10% upside. Key opportunities include M&A synergies and digital banking growth, though risks remain from integration challenges and competitive pressures in regional banking markets. The stock's current valuation and growth trajectory support a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
